Champoux Jennifer 4

What Happened Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics (GLUE), exercised 2,175 stock options at a $3.98 strike (cost $8,657) on 2026-06-23 and sold the 2,175 shares the same day at $20.00 each, generating $43,500 in gross proceeds. Net proceeds before taxes and fees were roughly $34,843 (sale proceeds minus exercise cost). The sale appears to be a routine disposition executed under a pre-established trading plan.

Key Details

• Transaction date: 2026-06-23; Form 4 filed 2026-06-25 (timely).
• Exercises: 2,175 shares acquired via option exercise at $3.98 (code M) — cost $8,657.
• Sale: 2,175 shares sold at $20.00 (code S) — proceeds $43,500.
• A derivative/cancelation line shows 2,175 option units disposed at $0 (reflects the option conversion on exercise).
• Footnotes: (F1) Transactions were made pursuant to a Rule 10b5-1 trading plan adopted Feb 19, 2026. (F2) Option vesting: 25% vested May 28, 2025, remainder vesting monthly over 36 months, subject to continued service.
• Shares owned after the transactions: not disclosed in the provided filing excerpt.

Context

• This was an option exercise immediately followed by an open-market sale (commonly a cashless exercise + sale). Such transactions often reflect planned liquidity rather than a directional signal about company prospects.
• Transaction codes: M = option exercise/conversion, S = sale. The use of a 10b5-1 plan indicates the sale was pre-authorized according to a written plan adopted before the trades.